All Recipharm facilities ready for EU serialisation, regardless of Brexit15 Feb 2019
The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.
Recipharm has announced that all 15 of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe ahead of the 9 February deadline.
During the period 2016-2018, the CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers, ahead of the introduction of the EU Falsified Medicines Directive (EU FMD) and the US Drug Supply Chain Security Act (DSCSA).
In addition, all of the facilities are connected to customers to allow them to report serial numbers. The facilities are located across Europe in France, Italy, Sweden, Spain, Germany, the UK and Portugal, as well as in India.
Staffan Widengren, Director Corporate Projects, said: “Recipharm has been very committed to meeting compliance deadlines, establishing a dedicated task force 3 years ago. A lot of time and effort has gone into our preparations so it’s rewarding to report that we are ready, especially ahead of the enforcement date.”
“Standardising our serialisation capabilities has enabled us to provide a seamless and flexible service to our customers, across multiple markets.”
After months of operational upheaval, the EU FMD regulation is now in effect. As CDMOs try to adhere to serialization requirements, how could Brexit affect the new regulations and how does Recipharm aims to handle products during this period?
"The uncertainty of Brexit lingers, pharmaceutical companies are still unsure as to how Brexit will affect the FMD requirements, said Staffan Widengren. He continued: "When the UK leaves the EU on Friday 29 March, it could be that the UK market does not require serialised products, whereas the EU will uphold the regulations. This means that when drug products are transferred from the UK to the EU market, they will still need to comply with FMD requirements.
"Ultimately, the operational approach of pharmaceutical firms will depend on whether the UK remains part of the current European Medicines Verification Organization (EMVO) or European Medicines Verification Systems (EMVS), like many of the European Election Studies (EES) countries, or if they decide to adopt a new and separate system.
"In the meantime, Recipharm will handle all products as EU products and report serial numbers to the EU Hub and national systems. It is imperative that pharma companies not yet compliant with the new regulation, outsource their serialisation requirements and co-operate with their partners as this will ultimately help to protect the safety of patients."
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
China relaxes import regulations to improve access and availability of affordable medicines
3 Sep 2019
The potential for generics to support the healthcare needs of China is significant.Read more
Exciting new vaccine targets killer disease TB
28 Aug 2019
Australian researchers produce early-stage vaccine which is inhaled into the lungs.Read more
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator
16 Aug 2019
Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.Read more
How real-world data can revolutionise drug development
9 Aug 2019
Utilising the current data environment and its data pools for the benefit of advancing research.Read more
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings
6 Aug 2019
The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.Read more
Mylan and Pfizer create new global pharma company
29 Jul 2019
The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.Read more
GSK opens new continuous manufacturing facilities in Singapore
11 Jul 2019
Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation